Literature DB >> 12019182

Adeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation.

Ramesh B Batchu1, Masood A Shammas, Jing Yi Wang, John Freeman, Nancy Rosen, Nikhil C Munshi.   

Abstract

Adeno-associated virus type 2 (AAV) is known to inhibit virally mediated oncogenic transformation. One of the early events of adenovirus (Ad) infection is the functional inactivation of cell cycle regulatory retinoblastoma (RB) family of proteins, which consists of retinoblastoma protein (pRB), p107, and p130. In an effort to understand the molecular basis of anti-oncogenic properties of AAV, we studied the effects of AAV expression on these proteins in cells infected with Ad. Western blot analysis showed that AAV interferes with the adenoviral-induced degradation and hyperphosphorylation of the pRB family of proteins in normal human fibroblasts as well as in HeLa and 293 cell lines. RNase protection assay showed enhanced expression of pocket protein gene by AAV expression. We also demonstrate that Rep proteins, the major AAV regulatory proteins, bind to E1A, the immediate early gene of Ad responsible for hyperphosphorylation and dissociation of pRB-E2F complex. This binding of AAV Rep proteins to E1A leads to decreased association between E1A and pRB leading to protection of pocket proteins from degradation, decreased expression of S phase genes and inhibition of cell cycle progression. These results suggest that the antiproliferative activity of AAV against Ad is mediated, at least in part, by effects of AAV Rep proteins on the Rb family of proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019182

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Authors:  M Ariel Kauss; Laura J Smith; Li Zhong; Arun Srivastava; K K Wong; Saswati Chatterjee
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

2.  Adeno-associated virus type 2 increases proteosome-dependent degradation of p21WAF1 in a human papillomavirus type 31b-positive cervical carcinoma line.

Authors:  Samina Alam; Ellora Sen; Heidi Brashear; Craig Meyers
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Adeno-associated virus type 2 induces apoptosis in human papillomavirus-infected cell lines but not in normal keratinocytes.

Authors:  Samina Alam; Craig Meyers
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

4.  Identification of cellular proteins that interact with the adeno-associated virus rep protein.

Authors:  Kevin Nash; Weijun Chen; Max Salganik; Nicholas Muzyczka
Journal:  J Virol       Date:  2008-10-29       Impact factor: 5.103

5.  Regulation of adeno-associated virus DNA replication by the cellular TAF-I/set complex.

Authors:  Gianluca Pegoraro; Alessandro Marcello; Michael P Myers; Mauro Giacca
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells.

Authors:  Samina Alam; Brian S Bowser; Michael J Conway; Mohd Israr; Apurva Tandon; Craig Meyers
Journal:  Mol Cancer       Date:  2011-08-09       Impact factor: 27.401

7.  Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Christopher S Bryant; Aamer M Qazi; Sanjeev Kumar; Sreedhar Chamala; Shu T Kung; Ramana S Sanka; Udaya S Puttagunta; Donald W Weaver; Scott A Gruber
Journal:  Pharmaceuticals (Basel)       Date:  2014-01-09

8.  Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination.

Authors:  Weiheng Su; Maria I Patrício; Margaret R Duffy; Jakub M Krakowiak; Leonard W Seymour; Ryan Cawood
Journal:  Nat Commun       Date:  2022-03-07       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.